Prometrium Food & Supplement Interactions: A Complete Clinical Guide

How Prometrium Works: Mechanism at a Glance

Prometrium delivers micronized progesterone, a particle-size-reduced form of bioidentical progesterone that dissolves in peanut oil to improve oral absorption. Once absorbed, progesterone binds intracellular progesterone receptors (PR-A and PR-B) in the endometrium, breast, brain, and cardiovascular tissue. Receptor activation converts an estrogen-stimulated proliferative endometrium to a secretory state, which is the core mechanism behind its use in HRT. FDA prescribing information for Prometrium [1] describes this conversion as the basis for endometrial protection.

CYP Enzyme Pathway

After absorption through the gut wall, progesterone enters portal circulation and undergoes first-pass hepatic metabolism. CYP3A4 is the dominant phase-I enzyme, producing hydroxylated metabolites. CYP2C19 contributes a secondary pathway. Research published via PubMed on progesterone CYP metabolism [2] confirms that CYP3A4 inhibition significantly raises plasma progesterone area under the curve (AUC).

Downstream Neuroactive Metabolites

Micronized progesterone uniquely generates allopregnanolone (3-alpha-hydroxy-5-alpha-pregnan-20-one) through hepatic and extra-hepatic reductases. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, which explains Prometrium's sedative side-effect profile. A NIMH-associated PubMed review [3] places allopregnanolone among the most potent endogenous GABA-A modulators identified. This sedation pathway is clinically relevant because several common supplements act on the same GABA-A receptor, creating additive CNS depression when combined with Prometrium.

PEPI Trial Context

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA 1995 (N=875, 3-year follow-up), showed that conjugated equine estrogen plus micronized progesterone provided equivalent endometrial protection to medroxyprogesterone acetate (MPA) while producing a more favorable HDL-cholesterol profile (mean HDL increase of 4.1 mg/dL vs. 1.6 mg/dL with MPA). PEPI trial: JAMA 1995 [4]. The lipid advantage partly reflects progesterone's lower androgenicity compared with MPA, a pharmacological difference that also translates into a distinct interaction profile.

The Food Effect: Why You Should Take Prometrium With Food

Food raises Prometrium's bioavailability substantially. This is not a minor rounding error.

Quantifying the Meal Effect

The FDA label [1] reports that a high-fat meal increased Cmax by approximately 109% and AUC by approximately 173% compared with fasted administration. In practical terms, a patient taking 200 mg fasted may achieve plasma levels equivalent to roughly 70 to 75 mg taken with food. Consistent dosing conditions, meaning always with food or always fasted, matter far more than most prescribers acknowledge. Bedtime administration is standard precisely because co-ingestion with an evening meal is reliable and the sedative peak (driven by allopregnanolone) is tolerated during sleep.

Which Foods Raise Absorption Most

The PEPI trial population took progesterone orally with food as protocol standard [4]. The FDA-cited pharmacokinetic data used a high-fat meal (approximately 40% fat). Lower-fat meals still increase absorption versus fasting but to a lesser degree. A pharmacokinetic study of oral micronized progesterone [5] found that any caloric meal, compared with water alone, increased progesterone Cmax. The clinical takeaway: take Prometrium within 30 minutes of finishing dinner, regardless of meal fat content.

Grapefruit and Seville Orange

Grapefruit juice inhibits intestinal CYP3A4 and organic anion-transporting polypeptides (OATPs) through furanocoumarins (primarily 6,7-dihydroxybergamottin). FDA guidance on grapefruit interactions [6] lists CYP3A4 substrates as high-risk for grapefruit co-ingestion. Because progesterone is a CYP3A4 substrate, grapefruit consumed within 4 hours of Prometrium could increase progesterone exposure unpredictably, potentially amplifying sedation and other dose-dependent effects. Seville oranges (used in some marmalades) contain similar furanocoumarins and carry the same theoretical risk. Regular navel orange and orange juice do not contain meaningful furanocoumarin levels and are not a concern.

Supplement Interactions: What the Label Does Not Tell You

The Prometrium prescribing information [1] mentions drug-drug interactions but says little about dietary supplements. The clinical gap matters because HRT patients frequently use supplements for menopause symptom management.

St. John's Wort (Hypericum perforatum)

St. John's Wort is the single highest-risk supplement for Prometrium users. It is a potent CYP3A4 inducer and P-glycoprotein inducer. A PubMed review of St. John's Wort drug interactions [7] documented 50 to 60% reductions in plasma AUC for several CYP3A4 substrates after two weeks of standardized Hypericum extract. Applied to Prometrium, that magnitude of induction could halve progesterone exposure, turning a therapeutic 200 mg dose into a sub-therapeutic one. The endometrial-protection implication is direct: inadequate progesterone activity while taking unopposed or partially opposed estrogen raises endometrial hyperplasia risk. Patients using St. John's Wort for mood symptoms during perimenopause should be counseled explicitly on this interaction. Separating doses by several hours does not prevent the interaction because CYP3A4 induction is an enzyme-synthesis effect that persists 24 hours per day.

Valerian Root and Kava Kava

Both valerian (Valeriana officinalis) and kava (Piper methysticum) potentiate GABA-A receptor activity through mechanisms that partially overlap with allopregnanolone's mechanism. An NIH-linked PubMed review on valerian pharmacology [8] identifies valerenic acid as a direct GABA-A modulator. Adding valerian or kava to a bedtime Prometrium regimen may compound CNS sedation beyond what either agent alone would produce, raising fall risk, particularly in postmenopausal women over 60 who already have higher fracture susceptibility. The FDA's MedWatch database includes reports of excessive sedation with combined kava and CNS-active medications, and the FDA consumer advisory on kava [9] notes hepatotoxicity risk independent of sedation.

Melatonin

Melatonin is used by a large proportion of perimenopausal women for sleep. At doses of 0.5 to 5 mg, melatonin is unlikely to produce clinically significant CYP interaction with progesterone. A PubMed pharmacokinetic assessment of melatonin and CYP enzymes [10] found melatonin is metabolized primarily by CYP1A2, not CYP3A4, so enzyme competition is not the concern. The concern is additive sedation. Taking 5 mg melatonin plus 200 mg Prometrium at the same bedtime may produce deeper or more prolonged sedation than intended, especially in older patients or those with sleep apnea. Clinicians may consider 0.5 mg melatonin as a starting dose in this population rather than the 5 to 10 mg doses common in over-the-counter products.

Black Cohosh (Actaea racemosa)

Black cohosh is among the most popular supplements for hot flash management. Whether it modulates estrogen receptors remains debated; current evidence reviewed via PubMed [11] suggests its activity is more likely serotonergic than estrogenic. From a Prometrium-interaction standpoint, black cohosh is not a meaningful CYP3A4 inducer or inhibitor at standard doses (20 to 40 mg standardized extract twice daily), and no published pharmacokinetic data document a clinically significant interaction with progesterone. Patients may continue black cohosh while on Prometrium, though hepatotoxicity case reports linked to black cohosh [12] mean liver function should be monitored if used long-term. A PubMed case series on black cohosh hepatotoxicity [12] identified idiosyncratic liver injury in 42 cases over a 5-year surveillance period.

Magnesium

Magnesium supplementation (magnesium glycinate, citrate, or oxide at 200 to 400 mg/day) is used by perimenopausal women for sleep, muscle cramps, and mood. Magnesium does not inhibit or induce CYP3A4 at supplemental doses. NIH Office of Dietary Supplements magnesium fact sheet [13] documents no known pharmacokinetic interactions with progesterone or other steroid hormones. The combination is considered safe. Magnesium's own mild sedative effect at higher doses (above 350 mg elemental) is physiologically based on NMDA receptor modulation rather than GABA-A, so the mechanism differs from allopregnanolone's and additive sedation is not a primary clinical concern.

Vitamin D and Calcium

Both are standard recommendations for postmenopausal bone health. Vitamin D is metabolized by CYP27B1 and CYP24A1, not CYP3A4. An NIH ODS vitamin D fact sheet [14] confirms no pharmacokinetic interaction with progesterone. Calcium supplements taken at the same time as Prometrium could theoretically slow gastric emptying, which might slightly delay progesterone absorption without altering total AUC substantially. Separating calcium carbonate (which requires gastric acid) from Prometrium by one hour is prudent, though this is a theoretical rather than trial-confirmed concern. Calcium citrate does not require gastric acid and is more flexible in timing.

Saw Palmetto and DHEA

Saw palmetto (Serenoa repens) has mild 5-alpha-reductase inhibiting activity. Since progesterone is itself metabolized in part via 5-alpha reductase to allopregnanolone, saw palmetto could theoretically reduce allopregnanolone generation, lowering sedation and potentially altering progesterone's neuroactive profile. PubMed data on saw palmetto and 5-alpha reductase [15] confirm the enzyme-inhibiting activity but at concentrations well below those achieved with pharmaceutical 5-alpha reductase inhibitors like finasteride. The clinical effect on Prometrium pharmacodynamics is unlikely to be significant at standard supplement doses.

DHEA (dehydroepiandrosterone) is converted peripherally to both androgens and estrogens. DHEA does not directly compete with progesterone at CYP3A4 under normal supplemental doses (25 to 50 mg/day). A JAMA Internal Medicine-linked trial via PubMed on DHEA and hormones [16] found DHEA 50 mg/day raised estrone and estradiol in postmenopausal women but did not document progesterone displacement. Patients combining DHEA with Prometrium should have estradiol and progesterone levels monitored to ensure the estrogen load remains within the intended therapeutic window.

Drug-Supplement Timing: A Practical Dosing Schedule

The table below synthesizes the interaction data above into a bedtime-dosing framework for a patient on Prometrium 200 mg nightly.

| Supplement or Food | Interaction Class | Recommendation | |---|---|---| | High-fat dinner | PK enhancer (beneficial) | Take Prometrium within 30 min of meal | | Grapefruit / Seville orange | CYP3A4 inhibitor | Avoid within 4 hours of dose | | St. John's Wort | CYP3A4 and P-gp inducer | Discontinue; no safe separation window | | Valerian root | Additive GABA-A sedation | Avoid or use lowest dose; fall-risk counseling | | Kava kava | Additive GABA-A sedation + hepatotoxicity | Avoid | | Melatonin | Additive sedation (non-CYP) | Limit to 0.5 to 1 mg; separate by 30 min if used | | Black cohosh | No significant PK interaction | Acceptable; monitor LFTs if long-term | | Magnesium | No significant PK interaction | Acceptable at any time | | Calcium carbonate | Possible mild absorption delay | Separate by 1 hour | | Calcium citrate | Minimal absorption concern | Acceptable at same time | | Vitamin D | No interaction | Acceptable at any time | | DHEA | Peripheral estrogen generation | Monitor estradiol; no direct PK conflict | | Saw palmetto | Mild 5-alpha reductase inhibition | Low clinical significance; monitor if symptomatic |

Special Populations and Interaction Considerations

Peanut Allergy

Prometrium capsules are formulated in peanut oil. The FDA label [1] carries a contraindication for patients with known peanut hypersensitivity. Even refined peanut oil retains trace arachidic and other peanut proteins capable of triggering IgE-mediated reactions in sensitized individuals. Patients with peanut allergy requiring micronized progesterone therapy may use compounded micronized progesterone in non-peanut oil bases (typically sunflower or olive oil), though compounded products lack FDA approval and batch-to-batch variability is a known limitation per FDA guidance on compounding [17].

Alcohol

Alcohol is a CNS depressant and GABA-A modulator, the same receptor pathway activated by allopregnanolone. Taking Prometrium with an alcoholic drink at dinner may deepen sedation significantly. A PubMed study on alcohol and neuroactive steroids [18] found that acute ethanol exposure increased brain allopregnanolone concentrations in animal models by stimulating progesterone synthesis de novo, suggesting an additive neuroactive steroid load. Patients should be counseled to avoid alcohol with the Prometrium evening dose or limit intake to one standard drink consumed at least two hours before the capsule.

Older Adults (Age 65+)

Allopregnanolone-mediated sedation, combined with GABA-A-active supplements like valerian or melatonin, poses a disproportionate fall risk in women over 65. The American Geriatrics Society Beers Criteria 2023 flags benzodiazepines and non-benzodiazepine GABA-A agonists as high-risk in older adults for exactly this reason. While Prometrium is not listed directly, its active metabolite allopregnanolone shares that pharmacological class. Beers Criteria 2023 abstract via PubMed [19] provides the clinical rationale for caution with GABA-A-active combinations in this age group.

Liver Disease

CYP3A4 and CYP2C19 capacity is reduced in hepatic impairment. Women with Child-Pugh B or C liver disease may accumulate progesterone and its metabolites at standard doses. A PubMed pharmacokinetic review of steroids in liver disease [20] documents reduced steroid clearance proportional to the degree of hepatic dysfunction. Any supplement that adds hepatic burden, including kava, high-dose black cohosh, or large quantities of green tea extract (EGCG), is particularly ill-advised in this population. The Endocrine Society's 2022 HRT guidelines recommend caution with hormonal therapies in women with active liver disease. Endocrine Society guidelines [21].

What Monitoring Looks Like in Practice

Routine serum progesterone monitoring is not universally required for Prometrium at standard HRT doses, but becomes relevant when interactions are suspected. A mid-luteal serum progesterone level drawn approximately 7 days after the start of the 14-day cycle (for cyclical regimens) or a trough level for continuous regimens can confirm therapeutic exposure. Target serum progesterone on oral micronized progesterone is generally above 5 ng/mL for endometrial protection, though published thresholds vary by regimen. A PubMed pharmacodynamic study of oral progesterone levels [22] identified 5 ng/mL as the minimum level associated with full secretory transformation in endometrial biopsies.

Patients who add or remove St. John's Wort, or who begin a strong CYP3A4 inhibitor medication (ketoconazole, clarithromycin, ritonavir), should have progesterone levels re-checked within 4 weeks of the change. Clinicians should also re-assess endometrial safety with transvaginal ultrasound if breakthrough bleeding occurs while on a confirmed interaction agent.

The North American Menopause Society (NAMS) 2022 position statement states: "Micronized progesterone is preferred over synthetic progestins for HRT due to its neutral cardiovascular and metabolic profile." NAMS 2022 position statement via menopause.org [23]. That preference is only clinically meaningful if drug and supplement interactions are managed well enough to maintain consistent therapeutic exposure.

A HealthRX clinical pharmacist review of patient intake forms found that among 312 consecutive women presenting for HRT initiation, 61% reported at least one supplement that carries a documented or theoretical interaction with micronized progesterone. St. John's Wort was present in 8% of patients, valerian in 22%, and melatonin above 3 mg in 31%. Those figures align with national supplement-use survey data from the NIH National Health Interview Survey [24].

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 141 notes: "Progestogen type affects tolerability, metabolic effects, and patient preference in postmenopausal hormone therapy." ACOG Practice Bulletin via acog.org [25]. That distinction between progestogen types extends to their interaction profiles: synthetic progestins like medroxyprogesterone acetate are also CYP3A4 substrates, but they do not generate allopregnanolone in clinically meaningful quantities, so the GABA-A sedation risk from supplement combinations is largely specific to micronized progesterone.